modelS01GX51
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | CromoglicicAcidCombinations | |
| ATC code: | S01GX51 | route: | ocular |
| compartments: | 1 | |
| dosage: | 20 | mg |
| volume of distribution: | 0.1 | L |
| clearance: | 1 | L/h/kg |
| other parameters in model implementation | ||
Cromoglicic acid, also known as cromolyn sodium, is a mast cell stabilizer used primarily to prevent allergic reactions, especially in the treatment of allergic conjunctivitis as eye drops. It acts by inhibiting the release of inflammatory mediators from mast cells. The combination product coded S01GX51 is used topically (ocular administration) for the symptomatic treatment of allergic conjunctivitis and other inflammatory eye disorders of allergic origin. While cromoglicic acid is approved for topical ocular and other uses in various regions, its usage has decreased with the availability of newer antihistamines, although it remains available and approved for specific indications.
Pharmacokinetics
No published pharmacokinetic (PK) studies are available specifically for cromoglicic acid combinations with ATC code S01GX51 in the context of ocular administration in humans. Available PK data are for systemic or other routes; ocular absorption is expected to be minimal with very low systemic bioavailability.
References
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)